Viral vectors and viral vaccines
Accelerating process development and scale-up for next-generation gene therapies and vaccines.
Get to market faster with CPI
At CPI, we support the development, scale-up, and characterisation of viral vectors and viral vaccines, enabling efficient, high-quality production for gene therapies, oncolytic viruses, and advanced vaccine platforms.
With expertise in upstream and downstream bioprocessing, analytical development, and regulatory compliance, we help you optimise viral vector manufacturing, ensuring stability, scalability, and clinical readiness.
Viral vectors and viral vaccines
Accelerating process development and scale-up for next-generation gene therapies and vaccines.
Get to market faster with CPI
At CPI, we support the development, scale-up, and characterisation of viral vectors and viral vaccines, enabling efficient, high-quality production for gene therapies, oncolytic viruses, and advanced vaccine platforms.
With expertise in upstream and downstream bioprocessing, analytical development, and regulatory compliance, we help you optimise viral vector manufacturing, ensuring stability, scalability, and clinical readiness.
Viral vectors and viral vaccines
Accelerating process development and scale-up for next-generation gene therapies and vaccines.
Get to market faster with CPI
At CPI, we support the development, scale-up, and characterisation of viral vectors and viral vaccines, enabling efficient, high-quality production for gene therapies, oncolytic viruses, and advanced vaccine platforms.
With expertise in upstream and downstream bioprocessing, analytical development, and regulatory compliance, we help you optimise viral vector manufacturing, ensuring stability, scalability, and clinical readiness.
What we offer
Whether you need technical expertise, lab-based development, process optimisation, or regulatory guidance, our tailored approach ensures you have the right support at every stage.
Can't find what you're looking for?
With over 500 experts we are here to help.
500+
AAV, lentivirus and viral vaccine process development
Optimise the development and scale-up of viral vectors and vaccines with our expertise:
Upstream process development using transient transfection or stable cell lines.
High-throughput AMBR bioreactor systems for process optimisation.
Downstream purification and formulation to improve titre and stability.
Research cell bank generation and characterisation.
Process scalability up to 200L bioreactor systems.
These capabilities enhance yield, purity, and process consistency, supporting gene therapies and vaccine development.
Viral vector technology benchmarking and validation
De-risk your innovative technology with our independent testing and benchmarking services:
Alpha and beta testing of viral vector production platforms.
Side-by-side comparisons of process efficiency and scalability.
Proof-of-concept studies for novel viral vector technologies.
Analytical characterisation of viral titres, potency, and integrity.
Our expertise ensures objective, data-driven validation of novel viral vector technologies, helping you to demonstrate performance, build industry credibility, and accelerate market adoption.
Analytical development and characterisation
Ensure the quality, consistency, and stability of viral vectors and vaccines with our advanced analytical capabilities:
Purity and titre assessments using ddPCR, ELISA, and SEC-MALS.
Empty/full capsid ratio analysis for AAV vectors.
Stability and degradation studies under real-time conditions.
High-resolution characterisation using next-generation sequencing (NGS).
These capabilities ensure regulatory compliance and optimise batch-to-batch consistency.
What we offer
Whether you need technical expertise, lab-based development, process optimisation, or regulatory guidance, our tailored approach ensures you have the right support at every stage.
AAV, lentivirus and viral vaccine process development
Optimise the development and scale-up of viral vectors and vaccines with our expertise:
Upstream process development using transient transfection or stable cell lines.
High-throughput AMBR bioreactor systems for process optimisation.
Downstream purification and formulation to improve titre and stability.
Research cell bank generation and characterisation.
Process scalability up to 200L bioreactor systems.
These capabilities enhance yield, purity, and process consistency, supporting gene therapies and vaccine development.
Viral vector technology benchmarking and validation
De-risk your innovative technology with our independent testing and benchmarking services:
Alpha and beta testing of viral vector production platforms.
Side-by-side comparisons of process efficiency and scalability.
Proof-of-concept studies for novel viral vector technologies.
Analytical characterisation of viral titres, potency, and integrity.
Our expertise ensures objective, data-driven validation of novel viral vector technologies, helping you to demonstrate performance, build industry credibility, and accelerate market adoption.
Analytical development and characterisation
Ensure the quality, consistency, and stability of viral vectors and vaccines with our advanced analytical capabilities:
Purity and titre assessments using ddPCR, ELISA, and SEC-MALS.
Empty/full capsid ratio analysis for AAV vectors.
Stability and degradation studies under real-time conditions.
High-resolution characterisation using next-generation sequencing (NGS).
These capabilities ensure regulatory compliance and optimise batch-to-batch consistency.
Can't find what you're looking for?
With over 500 experts we are here to help.
500+
What we offer
Whether you need technical expertise, lab-based development, process optimisation, or regulatory guidance, our tailored approach ensures you have the right support at every stage.
AAV, lentivirus and viral vaccine process development
Optimise the development and scale-up of viral vectors and vaccines with our expertise:
Upstream process development using transient transfection or stable cell lines.
High-throughput AMBR bioreactor systems for process optimisation.
Downstream purification and formulation to improve titre and stability.
Research cell bank generation and characterisation.
Process scalability up to 200L bioreactor systems.
These capabilities enhance yield, purity, and process consistency, supporting gene therapies and vaccine development.
Viral vector technology benchmarking and validation
De-risk your innovative technology with our independent testing and benchmarking services:
Alpha and beta testing of viral vector production platforms.
Side-by-side comparisons of process efficiency and scalability.
Proof-of-concept studies for novel viral vector technologies.
Analytical characterisation of viral titres, potency, and integrity.
Our expertise ensures objective, data-driven validation of novel viral vector technologies, helping you to demonstrate performance, build industry credibility, and accelerate market adoption.
Analytical development and characterisation
Ensure the quality, consistency, and stability of viral vectors and vaccines with our advanced analytical capabilities:
Purity and titre assessments using ddPCR, ELISA, and SEC-MALS.
Empty/full capsid ratio analysis for AAV vectors.
Stability and degradation studies under real-time conditions.
High-resolution characterisation using next-generation sequencing (NGS).
These capabilities ensure regulatory compliance and optimise batch-to-batch consistency.
Can't find what you're looking for?
With over 500 experts we are here to help.
500+
What we offer
Whether you need technical expertise, lab-based development, process optimisation, or regulatory guidance, our tailored approach ensures you have the right support at every stage.
Can't find what you're looking for?
With over 500 experts we are here to help.
500+
AAV, lentivirus and viral vaccine process development
Optimise the development and scale-up of viral vectors and vaccines with our expertise:
Upstream process development using transient transfection or stable cell lines.
High-throughput AMBR bioreactor systems for process optimisation.
Downstream purification and formulation to improve titre and stability.
Research cell bank generation and characterisation.
Process scalability up to 200L bioreactor systems.
These capabilities enhance yield, purity, and process consistency, supporting gene therapies and vaccine development.
Viral vector technology benchmarking and validation
De-risk your innovative technology with our independent testing and benchmarking services:
Alpha and beta testing of viral vector production platforms.
Side-by-side comparisons of process efficiency and scalability.
Proof-of-concept studies for novel viral vector technologies.
Analytical characterisation of viral titres, potency, and integrity.
Our expertise ensures objective, data-driven validation of novel viral vector technologies, helping you to demonstrate performance, build industry credibility, and accelerate market adoption.
Analytical development and characterisation
Ensure the quality, consistency, and stability of viral vectors and vaccines with our advanced analytical capabilities:
Purity and titre assessments using ddPCR, ELISA, and SEC-MALS.
Empty/full capsid ratio analysis for AAV vectors.
Stability and degradation studies under real-time conditions.
High-resolution characterisation using next-generation sequencing (NGS).
These capabilities ensure regulatory compliance and optimise batch-to-batch consistency.
Viral vectors and viral vaccines
applications
We enable innovation across a wide range of viral vector applications.
Gene therapies.
Viral vaccines.
Oncolytic viruses.
AAV & lentivirus delivery.
RNA-based therapeutics.
How we support you
From discovery to commercialisation, we enable scalable, cost-effective, and regulatory-compliant pharmaceutical innovations.
Can't find what you're looking for?
With over 500 experts we are here to help.
500+
Demonstrate the benefits of your viral vector innovation
Leverage our expertise to accelerate early-stage viral vector and vaccine development with:
Fast, cost-effective viral vector process development for securing funding.
Validation of your viral vectors in industry-relevant settings.
Integration of viral vector technologies into gene therapy pipelines.
Prove manufacturability and scalability
Ensure your viral vectors are scalable and reproducible with our expertise. With CPI, you can access:
Early-stage manufacturability assessments for gene therapies and vaccines.
Process optimisation for yield, stability, and cost-effectiveness.
Scalable production methods supporting preclinical and clinical development.
Assess and demonstrate commercial viability
We provide data-driven insights and process validation to secure funding and commercial partnerships. We support with:
Commercial feasibility assessments for viral vector production.
Validation of scale-up processes to secure funding and partnerships.
Transitioning from preclinical development to market launch.
Streamline regulatory compliance
We help to de-risk regulatory pathways, ensuring compliance with global standards. Our experts provide:
GMP-compliant viral vector manufacturing facilities.
Regulatory support for EMA, FDA, and MHRA approvals.
Quality assurance and documentation to mitigate risk.
Secure strategic partnerships
As a trusted UK Government partner, we have built a broad network across global leaders, emerging companies, large corporates, healthcare, and academia. We facilitate:
Access to world-class gene therapy and vaccine manufacturing partners.
Robust supply chains for viral vector production.
Collaborative projects tackling industry-wide challenges.
How we support you
From discovery to commercialisation, we enable scalable, cost-effective, and regulatory-compliant pharmaceutical innovations.
Can't find what you're looking for?
With over 500 experts we are here to help.
500+
Demonstrate the benefits of your viral vector innovation
Leverage our expertise to accelerate early-stage viral vector and vaccine development with:
Fast, cost-effective viral vector process development for securing funding.
Validation of your viral vectors in industry-relevant settings.
Integration of viral vector technologies into gene therapy pipelines.
Prove manufacturability and scalability
Ensure your viral vectors are scalable and reproducible with our expertise. With CPI, you can access:
Early-stage manufacturability assessments for gene therapies and vaccines.
Process optimisation for yield, stability, and cost-effectiveness.
Scalable production methods supporting preclinical and clinical development.
Assess and demonstrate commercial viability
We provide data-driven insights and process validation to secure funding and commercial partnerships. We support with:
Commercial feasibility assessments for viral vector production.
Validation of scale-up processes to secure funding and partnerships.
Transitioning from preclinical development to market launch.
Streamline regulatory compliance
We help to de-risk regulatory pathways, ensuring compliance with global standards. Our experts provide:
GMP-compliant viral vector manufacturing facilities.
Regulatory support for EMA, FDA, and MHRA approvals.
Quality assurance and documentation to mitigate risk.
Secure strategic partnerships
As a trusted UK Government partner, we have built a broad network across global leaders, emerging companies, large corporates, healthcare, and academia. We facilitate:
Access to world-class gene therapy and vaccine manufacturing partners.
Robust supply chains for viral vector production.
Collaborative projects tackling industry-wide challenges.
How we support you
From discovery to commercialisation, we enable scalable, cost-effective, and regulatory-compliant pharmaceutical innovations.
Demonstrate the benefits of your viral vector innovation
Leverage our expertise to accelerate early-stage viral vector and vaccine development with:
Fast, cost-effective viral vector process development for securing funding.
Validation of your viral vectors in industry-relevant settings.
Integration of viral vector technologies into gene therapy pipelines.
Prove manufacturability and scalability
Ensure your viral vectors are scalable and reproducible with our expertise. With CPI, you can access:
Early-stage manufacturability assessments for gene therapies and vaccines.
Process optimisation for yield, stability, and cost-effectiveness.
Scalable production methods supporting preclinical and clinical development.
Assess and demonstrate commercial viability
We provide data-driven insights and process validation to secure funding and commercial partnerships. We support with:
Commercial feasibility assessments for viral vector production.
Validation of scale-up processes to secure funding and partnerships.
Transitioning from preclinical development to market launch.
Streamline regulatory compliance
We help to de-risk regulatory pathways, ensuring compliance with global standards. Our experts provide:
GMP-compliant viral vector manufacturing facilities.
Regulatory support for EMA, FDA, and MHRA approvals.
Quality assurance and documentation to mitigate risk.
Secure strategic partnerships
As a trusted UK Government partner, we have built a broad network across global leaders, emerging companies, large corporates, healthcare, and academia. We facilitate:
Access to world-class gene therapy and vaccine manufacturing partners.
Robust supply chains for viral vector production.
Collaborative projects tackling industry-wide challenges.
Can't find what you're looking for?
With over 500 experts we are here to help.
500+
How we support you
From discovery to commercialisation, we enable scalable, cost-effective, and regulatory-compliant pharmaceutical innovations.
Demonstrate the benefits of your viral vector innovation
Leverage our expertise to accelerate early-stage viral vector and vaccine development with:
Fast, cost-effective viral vector process development for securing funding.
Validation of your viral vectors in industry-relevant settings.
Integration of viral vector technologies into gene therapy pipelines.
Prove manufacturability and scalability
Ensure your viral vectors are scalable and reproducible with our expertise. With CPI, you can access:
Early-stage manufacturability assessments for gene therapies and vaccines.
Process optimisation for yield, stability, and cost-effectiveness.
Scalable production methods supporting preclinical and clinical development.
Assess and demonstrate commercial viability
We provide data-driven insights and process validation to secure funding and commercial partnerships. We support with:
Commercial feasibility assessments for viral vector production.
Validation of scale-up processes to secure funding and partnerships.
Transitioning from preclinical development to market launch.
Streamline regulatory compliance
We help to de-risk regulatory pathways, ensuring compliance with global standards. Our experts provide:
GMP-compliant viral vector manufacturing facilities.
Regulatory support for EMA, FDA, and MHRA approvals.
Quality assurance and documentation to mitigate risk.
Secure strategic partnerships
As a trusted UK Government partner, we have built a broad network across global leaders, emerging companies, large corporates, healthcare, and academia. We facilitate:
Access to world-class gene therapy and vaccine manufacturing partners.
Robust supply chains for viral vector production.
Collaborative projects tackling industry-wide challenges.
Can't find what you're looking for?
With over 500 experts we are here to help.
500+
We are over 500 world-class innovation experts, scientists and engineers.
We are over 500 world-class innovation experts, scientists and engineers.
We are over 500 world-class innovation experts, scientists and engineers.
£3 billion of private investment unlocked
R&D projects delivered
Years of experience
Business collaborations
m² of facilities
Over £220m of innovation assets
£3 billion of private investment unlocked
R&D projects delivered
Years of experience
Business collaborations
m² of facilities
Over £220m of innovation assets
£3 billion of private investment unlocked
R&D projects delivered
Years of experience
Business collaborations
m² of facilities
Over £220m of innovation assets
Trusted by leading organisations
,
Why choose CPI?
Work with us to defer capital and workforce investments until your product or process is proven at scale.
Viral vector expertise
Proven success in gene therapy and vaccine development.
Industry-leading infrastructure
Supporting full-scale viral vector manufacturing.
Collaborative approach
We connect you with industry partners, funding opportunities, and regulatory insights to de-risk your journey.
End-to-end support
From early-stage development to clinical trials.
Get in touch
Let's innovate together
At CPI, we understand that every innovation, manufacturing process, and application is unique. Our flexible engagement model builds custom projects around your goals.
Philip Probert
Viral vectors and viral vaccines
Business Development
Get in touch
Let's innovate together
At CPI, we understand that every innovation, manufacturing process, and application is unique. Our flexible engagement model builds custom projects around your goals.
Philip Probert
Viral vectors and viral vaccines
Business Development
Get in touch
Let's innovate together
At CPI, we understand that every innovation, manufacturing process, and application is unique. Our flexible engagement model builds custom projects around your goals.
Philip Probert
Viral vectors and viral vaccines
Business Development
